Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study

Danielle Novetsky Friedman; Pamela J. Goodman; Wendy M. Leisenring; Lisa Diller; Susan L. Cohn; Rebecca M. Howell; Susan A. Smith; Emily S. Tonorezos; Suzanne L. Wolden; Joseph P. Neglia; Kirsten K. Ness; Todd M. Gibson; Paul C. Nathan; Lucie M. Turcotte; Brent R. Weil; Leslie L. Robison; Kevin C. Oeffinger; Gregory T. Armstrong; Charles A. Sklar; Tara O. Henderson

doi:10.1093/jnci/djae062

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Early efforts at risk-adapted therapy for neuroblastoma are predicted to result in differential late effects; the magnitude of these differences has not been well described.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Friedman et al. (2024) studied this question.

synapsesocial.com/papers/68e74f69b6db6435876c74c3 https://doi.org/10.1093/jnci/djae062

View at Publisher

Ask AI

Bookmark

Share

Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study

Ask about this paper

Abstract

Discussion

Cite This Study

Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading